Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Efficacy of a gastro-retentive bile acid sequestrant dosage form

A technology of bile acid chelating agent and gastric retention, which is applied in the direction of drug combination, pill delivery, medical preparations containing active ingredients, etc., and can solve the problem of incomplete response to PPI treatment

Inactive Publication Date: 2020-04-21
IRONWOOD PHARMA
View PDF32 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Some GERD patients do not fully respond to PPI therapy

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Efficacy of a gastro-retentive bile acid sequestrant dosage form
  • Efficacy of a gastro-retentive bile acid sequestrant dosage form
  • Efficacy of a gastro-retentive bile acid sequestrant dosage form

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0184] Example 1: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Finding Trial to Determine Oral Administration of Bile Acid Sequester Formulations in Patients with Symptomatic GERD Incompletely Responsive to Proton Pump Inhibitors for 8 Weeks safety and efficacy.

[0185] This example presents the protocol and results of a multicenter (approximately 60-80 centers in the United States), randomized, double-blind, placebo-controlled, parallel group, 8-week study consisting of 3 distinct periods (screening period up to 28 days; pretreatment period 14-21 days; treatment period 57 days). Such as figure 1 , the study included patients who had GERD and continued to experience GERD symptoms while receiving once-daily treatment with a proton pump inhibitor at the standard dose that the investigators considered optimized. Eligible patients continued to take PPIs and were randomized to either placebo or IW-3718 500 mg twice daily, IW-3718 1000 mg twice dai...

Embodiment 2

[0793] Example 2: A single-center, open-label, randomized, single-dose, 3-channel scintigraphy study in healthy subjects with 3 periods, each with a different phase designed to evaluate the in vivo performance of IW-3718 The in vivo performance of the breakfast composition, IW-3718, will be compared to that of an immediate release bile acid sequestrant in the fed state.

[0794] The purpose of this study was to compare the gastroprotective properties of a 500 mg IW-3718 tablet in the fed state compared to an immediate release formulation (Comparative Product Immediate Release Cholestagel [bile acid sequestrant; 625 mg]) . The gastrointestinal maintenance properties of the two drugs were studied after breakfast with different fat and calorie contents.

[0795] The recommended cholesterol dose is 6 x 625 mg tablets per day; the dose chosen in this study was 1 x 625 mg tablet in each of the 3 periods. This dose was well within the recommended daily dose, limiting exposure to he...

Embodiment 3

[1104] Example 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Range Exploratory Trial to Determine the Safety and Efficacy of Oral Bile Acid Sequestration Formulations in Patients with Gastroesophageal Reflux Disease for Up to 8 Weeks

[1105] eligibility criteria

[1106] Inclusion criteria

[1107] Each patient must meet all of the following criteria to be eligible to participate in this study:

[1108] Patients had signed the ICF prior to performing any study-specific procedures.

[1109] Patients were nonhospitalized male or female (if female, not pregnant) and at least 18 years old at the screening visit.

[1110] Patients had a diagnosis of GERD and reported experiencing GERD symptoms (heartburn or regurgitation) on average > 4 days per week in the last 8 weeks prior to the Screening Visit.

[1111] Patients had received standard labeled dose, QD, PPI therapy (which, in the investigator's judgment, could not be further improved by changing the b...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
Login to View More

Abstract

Methods and formulations of reducing one or more symptoms of gastroesophageal reflux disease (GERD) in a human patient with symptomatic GERD not completely responsive to proton pump inhibitors (PPIs).The patient is administered a therapeutically effective amount of an enteric coated gastro-retentive oral dosage form in the form of a tablet of a bile acid sequestrant dispersed in a polymeric matrix consisting essentially of poly(alkylene)oxide and one or more filler or compressing agent such that the patient experiences a clinically meaningful reduction in one or more symptoms of GERD.

Description

technical field [0001] The present invention relates, inter alia, to methods of treating eg GERD using gastroretentive oral dosage forms comprising bile acid sequestrants. Background technique [0002] Bile reflux occurs when bile travels up (refluxes) from the small intestine into the stomach and then into the esophagus. When the lower esophageal sphincter (LES), which separates the esophagus from the stomach, malfunctions, bile acids can back up into the esophagus. [0003] A number of diseases and / or symptoms associated with bile reflux alone or with a combination of bile reflux and acid reflux; among others, these diseases and / or symptoms include gastroesophageal reflux disease or GERD, heartburn, indigestion, dyspepsia , erosive esophagitis, peptic ulcer, gastric ulcer, esophageal ulcer, esophagitis, laryngitis, pharyngitis, rough or hoarse voice, pulmonary dysfunction (such as cough and / or asthma) associated with GERD, Barrett's esophagus, Esophageal cancer (such as ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/20A61K9/00A61K9/28
CPCA61K9/284A61K9/2031A61K9/2054A61K9/2018A61K9/2059A61K9/2013A61K9/2009A61K31/785A61P1/04A61P1/16A61P11/04A61P1/14A61P35/00A61P1/00A61K45/06G01N33/743G01N2560/00A61K9/0065A61K2300/00A61K9/28
Inventor 马克·G·科里阿玛德·哈沙什伯纳德·约瑟夫·拉文斯迈克尔·霍尔席尔瓦·卡拉西克
Owner IRONWOOD PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com